Kornimate/medical-research-clean huggingface dataset:
recombinant human superoxide dismutase (rhsod) and vascular reactivity

Conditions: Inflammation

Summary: inflammation is characterised by an increased risk for cardiovascular events. dysfunction of the vascular endothelium caused by oxidative stress might provide a mechanistic link. in acute and chronic inflammation, oxidative stress occurs when the production of reactive oxygen species \[ros\] (including superoxide anions \[o2-\]) exceeds the capacity of the endogenous antioxidant defense systems, resulting in ros-mediated damage. recombinant human superoxide dismutase (rhsod) has shown potent antioxidant properties in in-vitro and animal studies and has been tested in phase i clinical trials in humans. rhsod could offer a therapeutic option for vascular dysfunction in diseases associated with increased oxidative stress. the investigators, therefore, want to test if the hyporesponsiveness to vasoactive drugs (norepinephrine, acetylcholine and glyceroltrinitrate) during acute inflammation by low-dose lipopolysaccharide (lps) is due to the increased production of superoxide anions, which could be scavanged by the radical scavenger rhsod.


Eligibility criteria:
inclusion criteria: * men aged between 18 and 45 years * nonsmokers * body mass index between 15th and 85th percentile * normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant exclusion criteria: * regular use of medication, abuse of alcoholic beverages, or participation in a clinical trial in the 3 weeks preceding the study * evidence of hypertension, pathologic hyperglycemia, or hyperlipidemia * treatment in the previous 3 weeks with any drug * symptoms of a clinically relevant illness in the 3 weeks before the first study day * history or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs * blood donation during the previous 3 weeks * history of hypersensitivity to the trial drug or to drugs with a similar chemical structure
a clinical trial evaluating the safety and efficacy of idp-110 in patients with acne vulgaris

Conditions: Acne Vulgaris

Summary: the purpose of this study is to assess the effectiveness of idp-110 in treating patients with acne vulgaris.


Eligibility criteria:
inclusion criteria: * presence of inflammatory and non-inflammatory lesions exclusion criteria: * dermatological conditions of the face other than acne that could interfere with clinical evaluations * female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
supplementation with nutrients modulating igf-1 and cytokines in elderly people at risk of undernutrition

Conditions: Undernutrition

Summary: the purpose of this study was to determine the improvement in nutritional status, especially in the level of insulin-like growth factor-1 (igf-1) and its relationship with changes in the circulating cytokine levels, after providing extra protein and energy contents to community-dwelling older adults at risk of undernutrition.

sixty of aged over 65 years, living independently in the community for elderly people, nondiabetic subjects with serum prealbumin of under 30 mg/dl and bmi under 25 kg/m2 were recruited. the subjects were followed for a 2-week pre-intervention period, followed by an intervention period, which they received 2 cartons of liquid oral nutritional supplementation daily for 2 weeks.

Eligibility criteria:
inclusion criteria: * voluntarily agree to participate and sign in informed consent form * aged 65 years or older * a serum prealbumin level≤30 mg/dl and a bmi\<25 kg/m2 exclusion criteria: * inability to perform oral ingestion * known allergies to milk or eggs * an inability to communicate, such as those with alzheimer's disease * malabsorption syndrome, a history of gastrectomy or enterectomy * diabetes, liver disease, renal disease, neurological disease, pancreatitis, malignancy, cardiovascular or cerebrovascular disease, metabolic syndrome * any other disease requiring treatment, medication or alcohol abuse * any condition that the investigator believes may put the subjects at under risk
effects of a 6-months physical conditioning program in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this randomized, controlled trial was to determine whether a (and if so which) physical conditioning program is effective to improve health status, physical activity, and quality of life in patients with cystic fibrosis. a positive effect of physical conditioning was expected.

a high level of physical activity might be beneficial for patients with cystic fibrosis (cf). several studies have indicated that physical training might improve fitness and lung functions (or, at least, slow the decline in lung functions). however, there are no long-term studies comparing the effects among aerobic training, strength training and no training. furthermore, motivation to continue a training with little variations between sessions has been shown to decline rapidly. thus, adherence with such a program may be low. finally, not all patients feel happy with the same program. therefore, a home-based individualized sports program might be best suitable to achieve long term benefits. the mukotrain study is a multicenter randomized controlled trial to determine the effects of a home-based physical training in patients with cf. comparisons: study a) patients training aerobically 3 \* 30 min per week (supervised in a sports club near their homes) in addition to their baseline physical activity compared to patients training upper and lower body strength 3 \* 30 min per week (supervised in a sports club near their homes) compared to patients maintaining their physical activity. the supervised intervention lasted 6 months, thereafter patients were followed for an additional 18 months. study b) patients asked to participate in sport activities at least 3 \* 60 min per week (free choice of activities) in addition to their baseline physical activity compared with patients asked to maintain their baseline physical activity.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cystic fibrosis * able to engage in intense physical activities exclusion criteria: * fev1 \<35%predicted * esophageal varicosis * pulmonary bullae * drop in arterial oxygen saturation with exercise \<80% * non-cf related chronic diseases * signs of pulmonary hypertension (ecg and echocardiogram)

Keywords: lung function test physical conditioning, human physical fitness quality of life
effectiveness of lumbopelvic stabilization exercises for pregnancy-related low back pain

Conditions: Pregnancy-related Low Back Pain

Summary: the purpose of this study is to examine the effectiveness of lumbopelvic stabilization exercises on women who have undergone caesarian sections on: 1) disability using the modified oswestry low back disability index (osw), 2) pain according to the numeric pain rating scale (nprs), 3) percent change of muscle thickness of the deep abdominals using ultrasound imaging, and 4) perceived improvement using the global rating of change (groc).

pregnancy-related low back pain is a very complex problem. decreased strength and endurance in the trunk and hip muscles have been shown in those with pregnancy-related low back pain. lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. however, there have been very few studies with post-partum women, specifically those who have undergone caesarian section births. the purpose of this study is to examine the effectiveness of lumbopelvic stabilization exercises on women who have undergone caesarian sections on: 1) disability using the modified oswestry low back disability index (osw), 2) pain according to the numeric pain rating scale (nprs), 3) percent change of muscle thickness of the deep abdominals using ultrasound imaging, and 4) perceived improvement using the global rating of change (groc).

Eligibility criteria:
inclusion criteria: * unilateral low back pain near the sacro-iliac joint (sij) (distal and/or lateral to l5-s1 in the buttocks) and/or symphysis pubis * pain onset during pregnancy or within 3 weeks of delivery * most recent delivery within 6-24 weeks * at least 2/6 positive sij provocation tests (thigh thrust, sacral compression, sacral distraction, sacral thrust, gaenslen's test) * positive active straight leg raise (aslr) test. exclusion criteria: * neurological signs * systemic disease * currently pregnant

Keywords: stabilization exercises
effect of albis on gastroduodenal mucosal injury in patients receiving dual antiplatelet therapy after percutaneous coronary intervention

Conditions: Gastritis; Gastroduodenal Ulcer

Summary: the purpose of this study is to evaluate effectiveness of albis on gastroduodenal mucosal injury in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.


Eligibility criteria:
inclusion criteria: * age between 20 and 80 years * patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks * modified lanza score grade 0-1 measured by upper gastrointestinal endoscopy * mild gastrointestinal symptom * creatinen in blood ≤ 3mg/dl * bun ≤ 50mg/dl * birilubin ≤ 3mg/dl * ast and alt ≤ 80u/l exclusion criteria: * pregnant or breast feeding * history of stomach or esophagus surgery * peptic ulcer or reflux esophagitis * zollinger-ellison syndrome or primary esophageal motility disorders * malignant tumor * bleeding tendency or coagulopathy * contraindication of albis * long term use of aspirin or p2y12 receptor antagonist within 1month * patients who tool medicine such as ppi, apa,h2blocker, muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, bisphosphonate agents, cytotoxic drug, nsaid, adrenal cortex hormone agents (topical treatment is allowed) * terminal patient

Keywords: gastritis gastroduodenal ulcer percutaneous coronary revascularization dual antiplatelet therapy
the effect of astaxanthin on oxidative stress indices in patients with polycystic ovary syndrome

Conditions: PCOS

Summary: polycystic ovary syndrome (pcos) is the most common endocrinopathy affecting women of reproductive age it is hypothesized that ∼20 fold increase in reactive oxygen species (ros) generation in follicular fluid (ff) and granulosa cells of pcos women plays an adverse role in affecting the ivf success rate. astaxanthin (3,3'-dihydroxy-β,β'-carotene-4,4'-dione) is a nonprovitamin a carotenoid classified as a xanthophyll and is found in high amounts in the red pigment of crustacean shells (e.g., crabs, shrimp), salmon, trout, and asteroides. it has been demonstrated that astaxanthin displays a wide variety of biological activities, including anti-oxidative, anticancer, and anti-inflammatory effects. investigators aim to investigate the effect on astaxanthin administrating on reducing of ros in ff and induction of antioxidant response elements in pcos women.


Eligibility criteria:
inclusion criteria: diagnosed pcos cases according to the national institute of health criteria (nih consensus criteria) and rotterdam criteria exclusion criteria: * menopause, pregnant or lactating females * individuals with diabetes * those with hepatic,renal, thyroid or cardiovascular disorders * patients with elevated levels of prolactin * those who were taking antioxidant supplements within the last 3 months

Keywords: pcos astaxanthin ros
microneedling vs dermabrasion for early facial scar resurfacing

Conditions: Scar

Summary: this study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.

microneedling and dermabrasion are two common modalities that may be performed in-office to treat surgical scars. microneedling is a form of collagen induction therapy, often used in conjunction with platelet-rich plasma or hyaluronic acid. dermabrasion is a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization. to determine which modality is most effective, a prospective study; randomizing a volunteer sample of adult patients with new surgical vertical forehead scars will receive either dermabrasion or microneedling in the early postoperative period.

Eligibility criteria:
inclusion criteria: * volunteer adult patients will be identified by visiting the facial plastics and reconstructive surgery clinic at atrium health wake forest baptist. * patients will be 18 years old+ and have a vertical surgical scar in the superior 1/3 of the face (trichion to glabella). * patients will enroll in the clinic research registry and indicate an interest in being involved in the study. exclusion criteria: * patients who rate types 4-6 on the fitzpatrick scale will be excluded due to risk of poor outcome from dermabrasion. * there are no other planned exclusion criteria. patients will not be excluded on the basis of gender, race/ethnicity, or age, provided that they meet the described inclusion criteria.

Keywords: dermabrasion microneedling surgical scars
a study to investigate the effect of food on the bioavailability of a capsid inhibitor (cai) in male and female healthy participants

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the bioavailability of cai vh4011499.


Eligibility criteria:
inclusion criteria: * participants who are 18 to 55 years of age. * participants who are overtly healthy. * one sars-cov-2 negative test is required prior to dosing * body weight within 50-100 kg and body mass index (bmi) within the range 19-32 kg/m2 (inclusive). * capable of giving signed informed consent. * participants male at birth must use male condoms, and participants female at birth who are of childbearing potential must be using acceptable forms of birth control. exclusion criteria: * history or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs. * current or chronic liver disease, hepatic or biliary abnormalities, or relevant hepatitis. * abnormal blood pressure. * any malignancy within the past 5 years except certain localized malignancies, or breast cancer within the past 10 years. participants with exclusionary electrocardiogram findings.positive hiv test or ongoing behaviors that put the participant at high risk for hiv acquisition. * participants who are breastfeeding or plan to become pregnant during the study. * past or intended use of exclusionary medications or vaccines. * exposure to \>4 new investigational products within 12 months, previous participation in this study, or current enrolment or participation in another investigational study. * alt \>1.5x upper limit of normal (uln), total bilirubin \>1.5x uln, and/or estimated serum creatinine clearance \<60 ml/min. * history of or current infection with hepatitis b or hepatitis c. * positive sars-cov-2 test, having signs and symptoms suggestive of covid-19, or contact with known covid-19 positive person. * positive hiv antibody test. * participants with positive results for illicit drug use, regular use of drugs of abuse, tobacco or nicotine-containing product use, and/or excessive alcohol use.

Keywords: fasted condition fed condition bioavailability capsid inhibitor vh4011499
the quality of physiotherapy in low back pain patients in central finland

Conditions: Low Back Pain

Summary: chronic low back pain is one of the most common musculoskeletal disorders. in the finnish health 2000 survey the incidence of low back pain was 10% in men and 11% in women. several evidence-based rehabilitation guidelines recommend exercise therapy treatment of chronic back pain. however, there are no studies in chronic low back pain patients concerning the assessment of the content and quality of exercise modalities adviced in clinical practise. the aim of this study is to investigate the content and quality of physiotherapy management and advise in chronic low back pain patients in central finland.

the participants in this study are 100 working-age unspecific low back pain patients from the central health care district, who are referred for specialised care in the outpatient clinic in the department of physical medicine and rehabilitation in central finland hospital. the participants will be asked to complete health-related questionnaires and an in-house made questionnaire of their back rehabilitation. the main questions are: 1. the content about applied exercise modalities, 2. how the progression of exercises have been advised? 3. how pain was taken into account while exercising? the research will be carried out and coordinated by central finland central hospital, and the research project will take place between november 2014 and february 2019.

Eligibility criteria:
inclusion criteria: * experiencing chronic low back pain, * ability to communicate in finnish language exclusion criteria: * previous back surgery in the preceding 12-month * suspected or diagnosed lumbar disc herniation

Keywords: low back pain rehabilitation assessment quality
vaginal indomethacin for preterm labor

Conditions: Obstetric Labor, Premature

Summary: indometacin is a cyclooxygenase agent from the nsaid family that has been used to treat preterm contractions since the 70's by preventing the synthesis of prostaglandins. it has been shown to be significantly more effective than placebo and postpone labor for 7-10 days, prolong pregnancies above 37 weeks of gestation and reduce numbers of small for gestational age neonates. nifedipine is a calcium channel blocker agent that has been shown to reduce rates of labor within 48 hours from treatment. previous studies comparing rectal indometacin to oral nifedipine were inconclusive. prostaglandins are synthesized in the uterus and the uterine cervix and therefore local administration of indometacin may be more effective than other forms of administration, as been shown in a previous study. in this study we aim to compare vaginal indometacin administration to a commonly used tocolytic agent, nifedipine.


Eligibility criteria:
inclusion criteria: * singe fetus * gestational age between 24+0/7 and 31+6/7 * at least one uterine contraction in ten minutes for at least 20 minutes upon tocography admission * cervical parameters: 1 cm dilation or more or 80% cervical effacement or cervical length 20mm or less exclusion criteria: * rupture of membranes * vaginal bleeding * cervical dilation ≥5cm * known fetal malformations * fetal heart rate abnormalities * suspected placental abruption of adherent placental syndrome * known sensitivity to one of the drugs used in the study (indometacin and nifedipine) * maternal hypotension and known aortic or mitral stenosis * presence of cervical cerclage * previous administration of tocolytic drugs in current pregnancy

Keywords: preterm labor tocolysis prematurity
early diagnosis of gastric cancer cachexia

Conditions: Cachexia

Summary: gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. in cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. however, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. therefore, it is important to find biomarkers for early detection of cachexia. the investigators carried out a plasma-derived exosomal microrna(mirna) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. in gastric cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. however, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. therefore, it is important to find biomarkers for early detection of cachexia. the investigators carried out a plasma-derived exosomal microrna(mirna) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Eligibility criteria:
inclusion criteria: 1. patients with gastric cancer diagnosed by histopathology or cytopathology 2. complete clinical and pathological data 3. no previous or current mental illness or disturbance of consciousness exclusion criteria: 1. with multiple tumors or other malignant diseases 2. combined with other chronic wasting and metabolic diseases 3. past patients with non-tumor cachexia 4. people with mental illness or unable to cooperate
a study of the safety, tolerability, and pharmacokinetics of multiple doses of pf-05180999 in healthy adults

Conditions: Migraine

Summary: pf-05180999 is a novel phosphodiesterase-2 (pde2) inhibitor. the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pf-05180999 administered twice daily over 14 days. exploratory measures of pde2 inhibition will also be evaluated in blood and blister fluid.


Eligibility criteria:
inclusion criteria: * healthy male and/or female (of non-childbearing potential) subjects between the ages of 18 and 55 years * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs) exclusion criteria: * subjects with gilbert's disease or screening laboratory test results that deviate from the upper and/or lower limits of the reference or acceptable range. the exception is that all liver function tests must not exceed the upper limit of normal. * subjects with evidence of, or history of, hepatic disorder, including acute or chronic hepatitis b or hepatitis c. * subjects with very light skin or very dark skin (at the discretion of the investigator).

Keywords: pf-05180999 safety tolerability pharmacokinetics migraine pde2 camp cgmp cantharidin blister cyp3a induction
remaxol® used in the treatment of patients with gallstone disease complicated with obstructive jaundice

Conditions: Gallstone Disease; Obstructive Jaundice

Summary: obstructive jaundice is observed in 10-80 % of gallstone disease cases. the conventional tactics for the management of patients with obstructive jaundice is to remove biliary hypertension by using endoscopic or minimally invasive methods. the final surgical treatment is performed after jaundice reduction and normalization of hepatic functions. we suppose that the administration of the drug remaxol (inosine + meglumine + methionine + nicotinamide + succinic acid) during the perioperative period shortens jaundice duration and decreases the complications rate.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form. 2. age from 18 to 70 years 3. diagnosis: gallstone disease. cholelithiasis, choledocholithiasis. obstructive jaundice. 4. total bilirubin level in the blood in the range from 102.5 to 246 µmol/l. 5. jaundice duration according to the patient is not more than 7 days. 6. scheduled two-staged surgical treatment: 1) common bile duct decompression (endoscopic papillosphincterotomy and endoscopic lithoextraction); 2) laparoscopic cholecystectomy. exclusion criteria: 1. presence of other pathology causing jaundice syndrome (tumors, constrictions, etc.). 2. acute cholangitis. acute cholecystitis. acute pancreatitis. 3. history of chronic viral hepatitis, hepatic cirrhosis. 4. other surgical pathology aggravating the condition and/or requiring treatment. 5. use in the treatment of drugs containing ademethionine. 6. chf, functional class iii-iv according to nyha. 7. history of chronic kidney disease and/or creatinine level of more than 130 µmol/l. 8. respiratory failure. 9. impairment of consciousness. 10. diabetes mellitus. 11. psychic diseases. 12. autoimmune diseases. 13. tuberculosis, hiv infection. 14. pregnancy, lactation.

Keywords: gallstone disease obstructive jaundice remaxol